TR201818373A2 - Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇ - Google Patents

Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇

Info

Publication number
TR201818373A2
TR201818373A2 TR2018/18373A TR201818373A TR201818373A2 TR 201818373 A2 TR201818373 A2 TR 201818373A2 TR 2018/18373 A TR2018/18373 A TR 2018/18373A TR 201818373 A TR201818373 A TR 201818373A TR 201818373 A2 TR201818373 A2 TR 201818373A2
Authority
TR
Turkey
Prior art keywords
alzheimer
disease
diagnosis
biomarkers
minimal
Prior art date
Application number
TR2018/18373A
Other languages
English (en)
Inventor
Köseoğlu Emel
Gündoğdu Aycan
Ufuk Nalbantoğlu Özkan
Original Assignee
T C Erciyes Ueniversitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T C Erciyes Ueniversitesi filed Critical T C Erciyes Ueniversitesi
Priority to TR2018/18373A priority Critical patent/TR201818373A2/tr
Priority to PCT/TR2019/051001 priority patent/WO2020117164A1/en
Priority to EP19894370.6A priority patent/EP3877507B1/en
Publication of TR201818373A2 publication Critical patent/TR201818373A2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Buluş, Alzheimer hastalığının klinik teşhisi veya teşhise yardımcı karar destek sistemine ilişkindir. Buluşun dayalı olduğu teknik, belirgin klinik bulgu, insan proteini ve miRNA?sına yönelik ölçümlerden farklı olarak bağırsak mikrobiyomundaki belli bakteri genlerinin tespitine dayanmaktadır.
TR2018/18373A 2018-12-03 2018-12-03 Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇ TR201818373A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2018/18373A TR201818373A2 (tr) 2018-12-03 2018-12-03 Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇
PCT/TR2019/051001 WO2020117164A1 (en) 2018-12-03 2019-11-27 Minimal biomarkers and related next-generation sequencing kit for diagnosing alzheimer's disease from intestinal microbiome
EP19894370.6A EP3877507B1 (en) 2018-12-03 2019-11-27 Minimal biomarkers and related next-generation sequencing kit for diagnosing alzheimer's disease from intestinal microbiome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2018/18373A TR201818373A2 (tr) 2018-12-03 2018-12-03 Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇

Publications (1)

Publication Number Publication Date
TR201818373A2 true TR201818373A2 (tr) 2020-06-22

Family

ID=70975018

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/18373A TR201818373A2 (tr) 2018-12-03 2018-12-03 Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇

Country Status (3)

Country Link
EP (1) EP3877507B1 (tr)
TR (1) TR201818373A2 (tr)
WO (1) WO2020117164A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114657270B (zh) * 2022-02-23 2022-12-02 山东英盛生物技术有限公司 一种基于肠道菌群的阿尔茨海默病生物标志物及其应用
CN118028445A (zh) * 2022-11-03 2024-05-14 深圳先进技术研究院 一种基于肠道菌群的阿尔茨海默病生物标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201021399D0 (en) * 2010-12-16 2011-01-26 Genetic Analysis As Oligonucleotide probe set and methods of microbiota profiling
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10777320B2 (en) * 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
DK3171174T3 (en) 2015-11-20 2018-01-22 Geroa Diagnostics S L Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease
CN105603066B (zh) * 2016-01-13 2020-07-14 金锋 精神障碍的肠道微生物标志物及其应用

Also Published As

Publication number Publication date
WO2020117164A9 (en) 2021-04-15
EP3877507C0 (en) 2026-02-11
WO2020117164A1 (en) 2020-06-11
EP3877507A1 (en) 2021-09-15
EP3877507A4 (en) 2022-03-02
EP3877507B1 (en) 2026-02-11

Similar Documents

Publication Publication Date Title
Matos et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones
Garatachea et al. Genes, physical fitness and ageing
Kuperman et al. Dissecting asthma using focused transgenic modeling and functional genomics
Cetica et al. Patients with Griscelli syndrome and normal pigmentation identify RAB27A mutations that selectively disrupt MUNC13-4 binding
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
JP2017529859A5 (tr)
BR112012025870A2 (pt) uso de pelo menos uma razão quantitativa de dois diferentes peptídeos beta-amiloides, metodos e kit para determinar a probabilidade de um paciente contrair a doença de alzheimer (ad)
WO2017184895A3 (en) Compositions and methods related to κ180 dimethylated h1.0 protein
Meddeb et al. Homogeneous inflammatory gene profiles induced in human dermal fibroblasts in response to the three main species of Borrelia burgdorferi sensu lato
WO2020117164A9 (en) Minimal biomarkers and related next-generation sequencing kit for diagnosing alzheimer's disease from intestinal microbiome
JP2020517296A5 (tr)
EA201500526A1 (ru) Композиции и методы лечения воспалительных заболеваний инфекционного и неинфекционного происхождения
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
BR112021022421A2 (pt) Ensaio multiplex para determinar a razão de ss-amiloide 42/40 em espécimes de plasma humano
Pencheva et al. Pulmonary complications as a cause of death after renal transplantation
RU2017132290A (ru) Способ идентификации в иммунном репертуаре cdr3 участков, ассоциированных с заболеваниями
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
WO2020013233A1 (ja) Ａｌｓのバイオマーカーおよびａｌｓの診断方法
PL410454A1 (pl) Sposób identyfikowania odpowiedzi chorego na łuszczycę na leczenie genisteiną molekularny test oraz zastosowanie ekspresji genów do wykrywania in vitro łuszczycy
EA201992217A1 (ru) Белковый маркер для диагностики рака предстательной железы, способ измерения количества маркера и алгоритм интерпретации результата
Fadaee et al. Cannabinoid receptors as new targets for HTLV-1 associated myelopathy (HAM/TSP) treatment
CN204654989U (zh) 一种消化内科用超声胃镜
Burroughs et al. P04 Admission serum lactate is a strong predictor of outcome in cirrhotics admitted to intensive care unit, and when added to the liver-specific scores of model for end-stage liver disease or UK model for end-stage liver disease, improves their respective predictive value
HE et al. PRELIMINARY INVESTIGATIONS ON DISTINCT PROTEOMICS PROFILES FOR DIFFERENT SUBTYPES OF NON-SYNDROMIC CLEFT PALATE BASED ON SELDI-TOF-MS
Wierczeiko et al. A call for gene expression analysis in whole blood of patients with RA as biomarker for RA-ILD